STAT+: Wagering on FDA changes, Regenxbio will submit Duchenne gene therapy for approval (opens in new tab)
Regenxbio plans to submit its Duchenne gene therapy for FDA approval, just a month after it said that regulators wanted to see another trial.
Read the original article